Skip to main content
. 2021 Jun 21;125(4):534–546. doi: 10.1038/s41416-021-01450-6

Fig. 1. VTP causes tumour growth delay in TRAMP-C1 flank tumour allografts.

Fig. 1

a Outline schematic of treatment of subcutaneous flank TRAMP-C1 tumour allografts with VTP. b Growth kinetics of TRAMP-C1 tumours following indicated treatments (n = 7 untreated control; n = 10 VTP 9 mg/kg WST-11, 120 mW/cm2, 600 s). c Tumour growth delay to ≥400 mm3 analysis of TRAMP-C1 allograft tumours treated with VTP 9 mg/kg WST-11, 120 mW/cm2, 600 s. Data are presented as mean tumour volume ± SEM and analysed using ordinary one-way ANOVA with Tukey’s post hoc adjustment for multiple comparisons. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001. d Treatment of TRAMP-C1 tumour allografts with 9 mg/kg WST-11, 120 mW/cm2, for 600 s resulted in enhanced survival to a tumour size of 400 mm3 compared with untreated control tumours. e Median (range) body weight at start of experiment: untreated control = 21.2 g (20.2–23.5 g); VTP 9 mg/kg = 20.9 g (18.5–23.8 g).